Fortis Healthcare Limited (FORTIS) announced signing definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services to a new 400+ bedded super specialty hospital in Ashok Vihar, New Delhi. The hospital is expected to commence operations in 3-4 years, subject to necessary approvals.

Strategic Collaboration

The agreements have been executed by FHL’s wholly-owned subsidiary, Fortis Hospotel Limited (FHTL). Under the Healthcare Services Agreement (HSA), FHTL has long-term exclusive rights to provide specified inpatient healthcare services and specialized equipment such as Cath Lab, LINAC, PET-CT, Surgical Robot, etc. in consideration of an agreed service fee to be paid by SLJ Society.

Hospital Development

The hospital will be owned, operated, and managed by SLJ Society, with Fortis providing the healthcare services pursuant to the agreement. The land, building, and the associated civil and certain medical infrastructure will be owned and developed by the SLJ Society itself. For the purposes of construction, upgradation, and operation of the Hospital, FHTL will also provide a loan to the Society in a phased manner over the next 3-4 years based on construction progress.

Future Expansion

With a planned capacity of 400+ beds, which will be operationalized in phases, the hospital will be strategically located in one of Delhi’s key populous districts with a dense catchment in surrounding areas as well. The hospital will offer comprehensive and high-quality tertiary and quaternary healthcare services across key specialties, such as Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopaedics, Renal Sciences, multi-specialty robotic surgeries, and Transplants. It will also fulfill applicable regulatory and social obligations by providing free inpatient and outpatient treatment to eligible patients under the EWS (Economically Weaker Sections) category.

Dr. Ashutosh Raghuvanshi, MD & CEO of the Company, said, “the signing of the Healthcare Services Agreement with SLJ Society marks an important collaboration aimed at enhancing access to quality healthcare in North-West Delhi, an underserved micro-market characterized by a dense residential population. Under this arrangement, the hospital will be owned, operated, and managed by SLJ Society, with Fortis providing healthcare services pursuant to the agreement. Pursuant to this, Fortis’ services would extend to more than 3,400 beds across the Delhi – NCR region going forward. We remain focused on leveraging our clinical expertise and healthcare capabilities through strategic collaborations to support improved patient outcomes and access to high-quality care.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis falls 9.2% over three months and has not found a floor yet. The PEG reaches 3.02. The stock trades on brand and index weight, not on growth. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. The stock holds at 31% of its 52-week range with RSI at 33. In other words, neither side has a clear edge right now. Revenue grows at 13.3% and profits at 21.0% CAGR, with D/E of 0.00. Meanwhile, the stock dips 9.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Fortis Healthcare Limited.

Alkem Laboratories Limited (NSE: ALKEM) announced the launch of NeuCeno (cenobamate), a groundbreaking anti-seizure medication for the treatment of partial-onset seizures in adult patients. This marks the first time cenobamate is being introduced in India, signifying a major step forward in managing epilepsy. NeuCeno is available in various strengths, offering a once-daily oral therapy option. With an estimated 9.4 million people in India living with epilepsy, the launch of NeuCeno aims to address the unmet medical needs and improve the quality of life for patients.

Unique Mechanism of Action

NeuCeno (cenobamate) operates through a dual mechanism of action, selectively inhibiting the persistent sodium current and enhancing the brain’s natural inhibitory signaling. In clinical studies, adjunctive cenobamate demonstrated up to a 78% reduction in seizure frequency, with up to 30% of patients achieving seizure freedom during the maintenance phase. This significant efficacy underscores the potential of NeuCeno to transform treatment outcomes for patients with uncontrolled focal seizures.

Commitment to Patient Care

Sandeep Singh, Managing Director of Alkem Laboratories Limited, emphasized the company’s dedication to advancing high-quality, affordable medicines. He stated, ‘People living with epilepsy and their caregivers face significant challenges in achieving effective seizure control. Cenobamate has the potential to transform treatment outcomes towards delivering better epilepsy management.’ Alkem reaffirms its commitment to improving patient care by providing an important therapeutic option and supporting healthcare professionals in making informed treatment decisions.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alkem Laboratories Limited

Alkem Laboratories Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alkem trades in the lower quarter of its 52-week range. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The PEG of 0.87 signals undervaluation relative to growth. It is a potential re-rating candidate. The stock sits at 12% of its 52-week range, close to annual lows. Historically, value investors build positions at these levels — though cheap stocks can stay cheap. Revenue grows at 8.3% and profits at 32.7%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alkem Laboratories Limited.

Aurobindo Pharma Limited (NSE: AUROPHARMA) announced today that it has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 mcg and 80 mcg, a generic equivalent of QVAR® Inhalation Aerosol 40 mcg and 80 mcg, marketed by Teva Branded Pharmaceutical Products R&D LLC. This marks Aurobindo’s first metered-dose inhaler (MDI) product, signifying a significant milestone in the company’s expansion into complex respiratory therapies and strengthening its capabilities in the inhalation segment.

Manufacturing and Market Potential

The product will be manufactured at Aurobindo Pharma’s Raleigh facility in North Carolina, owned by its wholly-owned step-down subsidiary Aurolife Pharma LLC. The US market for the approved product and newer versions of the reference product, QVAR® Redi Haler, was estimated at US$301 million for the twelve months ended July 2026, according to IQVIA.

Therapeutic Benefits

Beclomethasone Dipropionate HFA Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Indicated for asthma patients who require systemic corticosteroid administration, where adding Beclomethasone Dipropionate HFA Inhalation Aerosol may reduce or eliminate the need for the systemic corticosteroids.

Building on our leadership in Generics, we are now expanding into complex inhalation therapies to create the next wave of differentiated growth in the US market, stated Aurobindo Pharma Limited.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Aurobindo Pharma Limited

Aurobindo Pharma Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Aurobindo rises 14.1% over three months, with buying pressure holding steady. Revenue grows at 10.7% and profits at 22.1% CAGR. The market consistently rewards this kind of compounding. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. The stock trades at 94% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 10.7%, profits at 22.1%, and the PEG sits at 1.19 — below its growth rate. That combination is rare. Check Fundamentals of Aurobindo Pharma Limited.